Ieq Capital LLC Buys 87,815 Shares of Johnson & Johnson $JNJ

Key Points

• Ieq Capital LLC has increased its stake in Johnson & Johnson by 56.8%, acquiring an additional 87,815 shares, bringing its total holdings to 242,513 shares worth approximately $40.2 million.
• Johnson & Johnson's quarterly earnings exceeded expectations, reporting $2.77 earnings per share and revenues of $23.74 billion, up 5.8% year-over-year.
• The company announced a quarterly dividend of $1.30 per share, with a dividend yield of 2.9%, payable on September 9th.

Ieq Capital LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 56.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 242,513 shares of the company's stock after acquiring an additional 87,815 shares during the quarter. Ieq Capital LLC's holdings in Johnson & Johnson were worth $40,218,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of JNJ. Nuveen LLC bought a new position in Johnson & Johnson during the first quarter worth $1,369,188,000. GAMMA Investing LLC increased its position in Johnson & Johnson by 24,450.4% during the first quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock worth $1,196,596,000 after acquiring an additional 7,185,977 shares during the period. Bank of New York Mellon Corp increased its position in Johnson & Johnson by 26.4% during the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after acquiring an additional 4,842,582 shares during the period. Janus Henderson Group PLC increased its holdings in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock valued at $1,149,536,000 after buying an additional 4,559,147 shares during the period. Finally, Pacer Advisors Inc. increased its holdings in Johnson & Johnson by 1,382.0% in the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock valued at $502,509,000 after buying an additional 2,825,626 shares during the period. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

NYSE JNJ traded down $1.29 on Thursday, hitting $175.50. 6,423,524 shares of the company were exchanged, compared to its average volume of 8,630,407. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The company has a market cap of $422.67 billion, a P/E ratio of 18.77, a P/E/G ratio of 2.25 and a beta of 0.41. The firm has a 50 day moving average of $165.45 and a two-hundred day moving average of $159.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the company posted $2.82 EPS. The company's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, May 13th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Citigroup boosted their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their target price for the company from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Guggenheim restated a "neutral" rating and issued a $167.00 target price (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average price target of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.